SCHEMBL30730713

SCHEMBL30730713

Cc1nccnc1CC(=O)N1CCC(c2nc(-c3ccc(F)cc3)no2)CC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.68
TSHR P16473 3/20 0.68
MAPK1 P28482 2/20 0.68
ALOX15 P16050 1/20 0.68
SMN1; SMN2 Q16637 4/20 0.55
ALDH1A1 P00352 1/20 0.55
TUBB4A P04350 1/20 0.55
TUBB P07437 1/20 0.55
TUBA3C P0DPH7 1/20 0.55
TUBA1B P68363 1/20 0.55
TUBA4A P68366 1/20 0.55
TUBB4B P68371 1/20 0.55
TUBB3 Q13509 1/20 0.55
TUBB2A Q13885 1/20 0.55
TUBB8 Q3ZCM7 1/20 0.55
TUBA3E Q6PEY2 1/20 0.55
TUBA1A Q71U36 1/20 0.55
TUBA1C Q9BQE3 1/20 0.55
TUBB6 Q9BUF5 1/20 0.55
TUBB2B Q9BVA1 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30730662 0.89 LMNA (0.71) LMNATSHRMAPK1ALOX15SMN1; SMN2
SCHEMBL30730463 0.86 LMNA (0.51) LMNATSHRMAPK1ALOX15SMN1; SMN2
SCHEMBL30730659 0.85 LMNA (0.68) LMNATSHRMAPK1ALOX15SMN1; SMN2
SCHEMBL30730698 0.84 LMNA (0.65) LMNATSHRMAPK1ALOX15SMN1; SMN2
SCHEMBL30730470 0.83 LMNA (0.68) LMNATSHRMAPK1ALOX15SMN1; SMN2
SCHEMBL30730558 0.83 LMNA (0.71) LMNATSHRMAPK1ALOX15SMN1; SMN2
SCHEMBL30730601 0.83 LMNA (0.71) LMNATSHRMAPK1ALOX15SMN1; SMN2
SCHEMBL30730542 0.81 LMNA (0.68) LMNATSHRMAPK1ALOX15SMN1; SMN2
SCHEMBL30730550 0.80 LMNA (0.67) LMNATSHRMAPK1ALOX15SMN1; SMN2
SCHEMBL30730694 0.80 LMNA (0.62) LMNATSHRMAPK1ALOX15SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 LMNA 1838/4885TSHR 620/4885MAPK1 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.